76285-74-0

Upstream product

• 61661-20-9 (E)-3-(4-chloro-benzylidene)-chroman-4-one 
• 118-93-4 o-hydroxyacetophenone 
• 104-88-1 4-chlorobenzaldehyde 
• 3033-96-3 4-chloro-2'-hydroxychalcone 
• 50-00-0 formaldehyd 
• 22105-07-3 3-(4-chlorophenyl)-1-(2-hydroxyphenyl)propan-1-one 
• 108-95-2 phenol 
• 3055-86-5 3-phenoxypropionitrile 
• 7170-38-9 3-phenoxypropanoic acid 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 

Downstream Products

• 1166789-94-1 3-(4-chlorobenzyl)chroman 
• 76285-81-9 4--3-(p-chlorobenzyl)chroman 
• 76285-83-1 4--3-(p-chlorobenzyl)chroman 
• 76300-27-1 4-(p-acetoxyphenyl)-3-(p-chlorobenzyl)chroman 
• 76285-78-4 4-(p-hydroxyphenyl)-3-(p-chlorobenzyl)chroman 
• 76285-76-2 3-(p-chlorobenzyl)-4-chromanol 

Relevant academic research and scientific papers

Synthesis, anticancer, structural, and computational docking studies of 3-benzylchroman-4-one derivatives

A series of 3-Benzylchroman-4-ones were synthesized and screened for anticancer activity by MTT assay. The compounds were evaluated against two cancerous cell lines BT549 (human breast carcinoma), HeLa (human cervical carcinoma), and one noncancerous cell

Synthesis and antirhinovirus activity of new 3-benzyl chromene and chroman derivatives

A series of 3-benzyl chromenes and chromans were synthesized and tested in vitro against human rhinovirus (HRV) 1B and 14, two representative serotypes for rhinovirus group B and A, respectively. All the new compounds, with the exception of 3-benzyl-2H-chromene (3a), showed a potent activity against HRV serotype 1B within micro or submicromolar range (IC50s from 0.11 to 6.62 μM). The low cytotoxicity of all the derivatives resulted in compounds with high therapeutic index (TI). On the contrary, HRV 14 infection was only weakly inhibited by the majority of these compounds. The 3-benzylidenechromans 2b and 2c showed the highest anti-HRV 1B activity (IC50 0.12 and 0.11 μM, respectively) coupled with remarkable TI (625.00 and 340.91, respectively). Mechanism of action studies on (Z)-3-(4-chlorobenzylidene)chroman (2b) suggest that the new compounds behave as capsid binders and interfere with very early stages of HRV 1B replication, similarly to related flavanoids.

Studies in Antifertility Agents: Part XXIX - synthesis of 4--3-benzylchromans

7-H/Methoxy-4-chromanones (1, 2), obtained by PPA cyclization of the respective β-aryloxypropionic acids, on treatment with araldehydes (3, 4) give the corresponding 3-arylidene-4-chromanones (5, 6).Catalytic hydrogenation of 5 and 6 over Pd-C (10percent) with one mole of hydrogen affords 3-benzyl-4-chromanones (7, 8), while hydrogenation of 6 yields 3-benzyl-7-methoxychroman (9).NaBH4 reduction of 7 and 8 gives the corresponding 4-chromanols (10, 11) as a mixture of 3,4-cis- and -trans-isomers, which are arylated as such with PhOH-AlCl3 to give 4-(p-hydroxyphenyl)chromans(12, 13) as the main products.Treatment of 12 and 13 with Ac2O-pyridine and with p-NO2C6H4COCl-pyridine yields the corresponding p-acetoxy (14, 15) and p-nitrobenzoyloxy (16, 17) derivatives.Alkylation of 12 and 13 with N-(β-chloroethyl)pyrrolidine hydrochloride furnishes the title compounds, 4--3-(p-chloro/H)benzyl-7-H/methoxy-chromans (18, 19).None of these compounds prevents pregnancy at 5 mg/kg dose in rats.